Aflibercept Injection, Solution
NDC Package 61755-950-00

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Aflibercept injection is aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This formulation utilizes a injection, solution delivery system. Marketed by Regeneron Pharmaceuticals, Inc., this product is identified by NDC 61755-950.

Identification & Billing

NDC Package Code
61755-950-00
Package Description
1000 mL in 1 BOTTLE
Product Code
61755-950
11-Digit Billing Format
61755095000

Clinical Specifications

Proprietary Name
Aflibercept
Non-Proprietary Name
Aflibercept
Substance Name
Aflibercept
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Active Ingredient(s)
AFLIBERCEPT 114.3 mg/mL
Usage Information
Aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

Regulatory & Marketing

Labeler Name
Regeneron Pharmaceuticals, Inc.
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
08-18-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61755-950-00 identifies a specific commercial package of 1000 ml in 1 bottle of Aflibercept (UNFINISHED drug), drug for further processing labeled by Regeneron Pharmaceuticals, Inc.. This injection, solution is formulated for use and contains aflibercept as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Regeneron Pharmaceuticals, Inc. on August 18, 2023. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Aflibercept is used to treat certain serious eye conditions (such as wet age-related macular degeneration, diabetic retinopathy/macular edema, macular edema following retinal vein occlusion). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.

How is this Regeneron Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61755095000. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61755-950-00
11-Digit CMS (5-4-2)
61755-0950-00

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.